Clinical Trials Logo

Ph1 Positive CML clinical trials

View clinical trials related to Ph1 Positive CML.

Filter by:
  • None
  • Page 1

NCT ID: NCT01159028 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The first goal of this clinical research study is to find the highest safe dose of BP1001, a liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS), for patients with Philadelphia Chromosome positive CML, AML, ALL and MDS. The response of the leukemia to this treatment will also be studied. The second goal of this clinical research study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent low-dose ara-C (LDAC) in patients with AML.